Jan 1970
Protected: Plex Platform Pipeline new
This content is password protected. To view it please enter your password below: Password:
Read more >
This content is password protected. To view it please enter your password below: Password:
Read more >This content is password protected. To view it please enter your password below: Password:
Read more >CONSISTENT CLINICAL RESULTS DEMONSTRATED ACROSS TRIALS POLYPID'S PHASE 3 CLINICAL TRIALS: D-PLEX100 – 311 – ( NCT04233424 ) – Abdominal / Colorectal surgery Efficacy and Safety of D-PLEX in the Prevention of Abdominal Surgery Incision Infection Post Colorectal Surgery. Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to assess Efficacy and Safety of…
Read more >CHASING ZERO: THE DRIVE TO ELIMINATE SURGICAL SITE INFECTIONSSSIs remain a substantial cause of morbidity, prolonged hospitalization, and death. SSI are the second most common hospital acquired infections in United States and the European Union and occur in approximately 2% to 5% of patients undergoing inpatient surgery worldwide 1. The incidence of SSI is doubled…
Read more >TREATMENT OF PERI-IMPLANTITIS - ONE OF THE MOST CHALLENGING Biofilm Metal Implant Chronic Infection Constant Contamination Mix Bacterial Makeup Primary efficacy endpoint: D-PLEX500 reduces Probe Pocket depth (PPD) vs. SoCD-PLEX500 prevented the loss of implants
Read more >Another product candidate from the PLEX-doxycycline family, for use in connection with orthopedic surgeries for the prevention of SSIs and support of bone recovery. [siteorigin_widget class="video_Widget"][/siteorigin_widget] D-PLEX1000 Showed Effective Treatment of Orthopedic Surgeries No deep bone infections after 6 months across 24 treated patients, in comparison with reported incidences in the literature ranging between 7%…
Read more >D-PLEX100 – PHASE 2 - SIGNIFICANT DECREASE IN THE RATE OF SSI IN ABDOMINAL SURGERIES Design: accessor and patient blinded and double-arm randomized study Objective: safety and efficacy of D-PLEX100 + SoC (n=101) vs. SoC alone (n=100) in prevention of incision infection post-colorectal surgery Primary efficacy end-point: the decrease of infection rate as measured by…
Read more >PolyPid’s ongoing clinical trials: D-PLEX100 – 301 – (NCT02731573) - Completed Initial Safety and Efficacy of D-PLEX100 in the Prevention of Primary Sternal Infection Post Cardiac Surgery. For more information, please visit clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02731573?term=D-PLEX&rank=1 D-PLEX100 – 302 – (NCT03558984) Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery For more information, please…
Read more >OUR PIPELINE IS DESIGNED TO ADDRESS DISEASES WITH HIGH UNMET MEDICAL NEEDS We paired our PLEX technology with drugs already approved by the U.S. FDA or innovative drug candidates POLYPID'S PHASE 3 CLINICAL TRIALS: SHIELD I ( NCT04233424 ) – Abdominal / Colorectal surgery Efficacy and Safety of D-PLEX100 in the Prevention of Abdominal Surgery…
Read more >LOCALIZED DRUG DELIVERY SYSTEM STUDIED FOR PREVENTION OF SSIs Active Ingredient: Doxycycline (broad-spectrum antibiotic) Release Duration: Prolonged effect of 30 days Indication: Prevention of abdominal incisional surgical site infection (SSI) Release profile: No burst, constant & linear release Dosing: Varies by incision size 1vial < 10cm, 10cm < 2vials > 20cm, 3 vials >20cm Negligible…
Read more >
PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.
Read More >
Is designed to prevent the risk of surgical site infections in both bone and soft tissue through its cutting-edge, local, extended-release mechanism
Read More >
Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.
Read More >